Volume 11, Number 9—September 2005
Research
Dengue Virus Type 3, Brazil, 2002
Table 2
Clinical specimen | RT-PCR positive/studied (%) | Virus isolation positive/studied (%) | Serotype detected | MAC-ELISA positive/studied | Immunohistochemistry positive/studied | Confirmed cases/studied cases (%) |
---|---|---|---|---|---|---|
Serum | 15/42 | 4/38 | 15 DENV-3 | 18/42 | ND | 26/42 (61.9) |
CSF | 1/ 2 | 0/2 | 1 DENV-3 | 0/2 | ND | 1/2 |
Fresh tissues | 17/59 | 2/59 | 17 DENV-3 | ND | ND | 17/59(28.8) |
Formalin-fixed and paraffin embedded tissues | ND | ND | 0 | 0 | 23/48 | 23/48 (47.9) |
Total | 33/103 (32.0) | 6/99 (6.0) | 33 DENV-3 | 18/44 (40.9) | 23/48 (47.9) | 40/62† (64.5) |
*RT-PCR, reverse transcriptase–polymerase chain reaction; MAC-ELISA, immunoglobulin M antigen capture enzyme-linked immunosorbent assay; DENV, dengue virus; IgG, immunoglobulin G; ND, not done; CSF cerebrospinal fluid.
†Total of confirmed fatal cases by any method/total of fatal cases studied.
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.